Xiaochun Wan | Tumor Immunology | Best Researcher Award

Published on by China Scientist

Prof. Xiaochun Wan | Tumor Immunology | Best Researcher Award

Dr. Xiaochun Wan is a distinguished immunologist and cancer researcher at the Chinese Academy of Sciences, serving as the Deputy Director of the Institute of Biomedicine and Biotechnology. With a Ph.D. in Immunology from the University of Montreal and postdoctoral training at the University of Pennsylvania, he has pioneered advancements in immune cell therapy, CAR-T technology, and monoclonal antibodies. His work has led to over 40 high-impact publications and 150+ patents, securing nearly RMB 200 million in research funding. Dr. Wan’s groundbreaking therapies have successfully treated 100+ cancer patients, positioning him as a leader in precision oncology and immunotherapy innovation.

Prof. Xiaochun Wan | ShenZhen Institute of Advance Technologies | China

Profile

SCOPUS ID

ORCID ID

🎓 Education

  • Dr. Xiaochun Wan earned his Ph.D. in Immunology from the University of Montreal in 2003. Following his doctoral studies, he pursued postdoctoral research at the University of Pennsylvania, focusing on advanced immunological therapies.

💼 Experience

  • Dr. Wan is a distinguished researcher at the Chinese Academy of Sciences and serves as the deputy director at the Institute of Biomedicine and Biotechnology. He is also the executive director of the Center for Protein and Cell-based Drugs at the Shenzhen Institutes of Advanced Technology. Before his current roles, he worked as a senior researcher at Merck, where he contributed to the development of monoclonal antibody-based drugs.

🔥 Awards and Achievements

  • Dr. Wan has received numerous prestigious awards, including the Canadian Institutes of Health Research (CIHR) Excellent Researcher Award and the International Federation of Clinical Immunology Conference Paper Award, recognizing his outstanding contributions to the field of immunology.

🛠️ Skills and Certifications

  • Dr. Wan specializes in immune cell therapy and monoclonal antibody research, with extensive expertise in drug development, clinical applications, and biotechnology innovation. His proficiency in translational medicine has significantly advanced therapeutic strategies for cancer treatment.

🔬 Research Focus

  • Dr. Wan’s research primarily focuses on immune cell therapy, particularly CAR-T cell technology, and monoclonal antibody development. He has published over 40 papers in leading journals such as JEM, Cancer Research, and the Journal of Immunology. With more than 150 patents to his name, he has secured substantial research funding from NSFC, Guangdong Province, and Shenzhen, totaling nearly RMB 200 million. In 2019, his team successfully submitted two national 1.1 major new drug IND applications. His CAR-T cell therapy has treated over 100 cancer patients, achieving internationally advanced clinical efficacy.

Conclusion

  • Dr. Wan’s dedication to advancing tumor immunology has led to life-saving therapies and transformative scientific discoveries. His combination of innovative research, real-world impact, and leadership in immunotherapy development positions him as an ideal recipient of this prestigious award. His work continues to shape the future of cancer treatment and immuno-oncology research globally.

📄Publications

  • Multifaceted roles of DLG3/SAP102 in neurophysiology, neurological disorders and tumorigenesis
    Authors: K.I. Gidado, F.O. Adeshakin, L. Rabiu, G. Zhang, X. Wan
    Journal: Neuroscience, 2025

  • CRISPR knock-in of a chimeric antigen receptor into GAPDH 3’UTR locus generates potent B7H3-specific NK-92MI cells
    Authors: L. Dai, P. Zhang, X. Niu, G. Zhang, X. Wan
    Journal: Cancer Gene Therapy, 2025

  • Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
    Authors: H.K. Tariq, Z. Liang, L. Rabiu, X. Wan, D. Yan
    Journal: Cells, 2025

  • MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
    Authors: N.M.F. Abdalsalam, A. Ibrahim, M.A. Saliu, X. Wan, D. Yan
    Journal: Cell Communication and Signaling, 2024

  • Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
    Authors: L. Rabiu, P. Zhang, L.O. Afolabi, G. Zhang, X. Wan
    Journal: Journal of Gastroenterology, 2024